𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Basal ganglia volume and clinical correlates in ‘preclinical’ Huntington’s disease

✍ Scribed by Caroline K. Jurgens; Lotte van de Wiel; Ad C. G. M. van Es; Yvette M. Grimbergen; Marie-Noëlle W. Witjes-Ané; Jeroen van der Grond; Huub A. M. Middelkoop; Raymund A. C. Roos

Publisher
Springer
Year
2008
Tongue
English
Weight
200 KB
Volume
255
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical correlates of mitochondrial fun
Clinical correlates of mitochondrial function in Huntington's disease muscle
✍ Christopher Turner; J. Mark Cooper; Anthony H. V. Schapira 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB

## Abstract Huntington's disease (HD) is caused by an abnormally expanded CAG repeat in the __IT__‐__15__ gene, which encodes a widely expressed protein called huntingtin. Abnormalities of mitochondrial respiratory chain function, specifically complex II/III, have been identified in HD striatum and

Open interconnected model of basal gangl
Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease
✍ D. Joel 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract The early stages of Huntington's disease (HD) present with motor, cognitive, and emotional symptoms. Correspondingly, current models implicate dysfunction of the motor, associative, and limbic basal ganglia‐thalamocortical circuits. Available data, however, indicate that in the early st

Basal ganglia atrophy in prodromal Hunti
Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation
✍ D.S. Adnan Majid; Adam R. Aron; Wesley Thompson; Sarah Sheldon; Samar Hamza; Die 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB

## Abstract Future clinical trials of neuroprotection in prodromal Huntington's (known as preHD) will require sensitive in vivo imaging biomarkers to track disease progression over the shortest period. Since basal ganglia atrophy is the most prominent structural characteristic of Huntington's patho

Gait variability and basal ganglia disor
Gait variability and basal ganglia disorders: Stride-to-stride variations of gait cycle timing in parkinson's disease and Huntington's disease
✍ Jeffrey M. Hausdorff; Merit E. Cudkowicz; Renée Firtion; Jeanne Y. Wei; Ary L. G 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 954 KB

## Abstract The basal ganglia are thought to play an important role in regulating motor programs involved in gait and in the fluidity and sequencing of movement. We postulated that the ability to maintain a steady gait, with low stride‐to‐stride variability of gait cycle timing and its subphases, w

Objective assessment of motor slowness i
Objective assessment of motor slowness in Huntington's disease: Clinical correlates and 2-year follow-up
✍ Jeroen P.P. van Vugt; Karlijne K.E. Piet; Liesbeth J. Vink; Sabine Siesling; Aei 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

## Abstract Functional disability of patients with Huntington's disease (HD) is determined by impairment of voluntary motor function rather than the presence of chorea. However, only few attempts have been made to quantify this motor impairment. By using a simple reaction time paradigm, we measured